All In Biotech

Drug Trial Radar · NCT07833098

A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase II Clinical Study to Evaluate the Efficacy and Safety of VB19055 in Participants With Hypertension (Including Resistant Hypertension) Whose Blood Pressure Remains Uncontrolled Despite Treatment With Two or More Antihypertensive Medications

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2027

Study completion Feb 2028

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).

Conditions

  • Hypertension
  • Resistant Hypertension
  • Uncontrolled Hypertension

Interventions

  • VB19055 Dose A QDDrug

    VB19055 Dose A orally once daily (QD) for 12 weeks

  • VB19055 Dose B QDDrug

    VB19055 DoseB orally once daily (QD) for 12 weeks

  • VB19055 Dose C QDDrug

    VB19055 Dose C orally once daily (QD) for 12 weeks

  • VB19055 placebo QDDrug

    VB19055 placebo orally once daily (QD) for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in seated clinic systolic blood pressure at Week 12.Time frame: at the end of the 12-week treatment period

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

    Baotou, China

  • Peking University People's Hospital

    Beijing, China

  • The Third Hospital of Changsha

    Changsha, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Chengdu Second People's Hospital

    Chengdu, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • Daqing People's Hospital

    Daqing, China

  • The First Hospital of Hebei Medical University

    Hebei, China

  • The First Affiliated Hospital of University of South China

    Hengyang, China

  • Affiliated Hospital of Jining Medical University

    Jining, China

  • The Third People's Hospital of Luoyang

    Luoyang, China

  • Zhongda Hospital, Southeast University

    Nanjing, China

  • Panjin Liaohe Oilfield Gem Flower Hospital

    Panjin, China

  • Qilu Hospital of Shandong University

    Shandong, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shanxi Cardiovascular Hospital

    Shaxi, China

  • Liaoning Provincial People's Hospital

    Shenyang, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Suzhou Municipal Hospital of Anhui Province

    Suzhou, China

  • China Resources WISCO General Hospital

    Wuhan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • The First People's Hospital of Xinxiang

    Xinxiang, China

  • The Seventh People's Hospital of Zhengzhou City

    Zhengzhou, China

  • Zhengzhou Central Hospital

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.